Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Survival of patients operated for colorectal liver metastases and concomitant extra-hepatic disease: External validation of a prognostic model

Academic Article
Publication Date:
2013
Short description:
Survival of patients operated for colorectal liver metastases and concomitant extra-hepatic disease: External validation of a prognostic model / Mavros, Mn; Hyder, O; Pulitano, C; Aldrighetti, L; Pawlik, Tm. - In: JOURNAL OF SURGICAL ONCOLOGY. - ISSN 0022-4790. - 107:5(2013), pp. 481-485. [10.1002/jso.23260]
abstract:
Background The presence of extra-hepatic disease (EHD) is no longer an absolute contraindication to surgery in patients with colorectal liver metastases (CRLM). Recently, a novel prognostic model predicting overall survival in such patients was proposed using five risk factors (EHD other than isolated lung metastases, CEA10ng/ml, >5 liver metastases, right colon as the primary CRC location, and diagnosis of EHD concomitant to CRLM recurrence). A bi-institutional database was used to perform an external validation of this model. Methods Ninety-seven patients operated for CRLM and EHD between 1982 and 2011 in two institutions was analyzed. The proposed prognostic model was validated in this cohort using Cox proportional hazards models and the concordance index (c). Results Of the five proposed risk factors, only EHD other than isolated lung metastases was found to independently predict overall survival [Hazards Ratio (HR)=2.10 (95% CI: 1.014.40)]. Although, the number of risk factors was marginally associated with overall survival in univariate analysis (P=0.049), the performance of the proposed prognostic model was poor when applied to our cohort (c=0.64). Conclusion The examined prognostic model of survival in patients with CRLM and EHD had poor performance. Further research is warranted to delineate the subset of patients who will benefit from surgery. J. Surg. Oncol. 2013;107:481485. (c) 2012 Wiley Periodicals, Inc.
Iris type:
1.1 Articolo in rivista
List of contributors:
Mavros, Mn; Hyder, O; Pulitano, C; Aldrighetti, L; Pawlik, Tm
Handle:
https://iris.unisr.it/handle/20.500.11768/94055
Published in:
JOURNAL OF SURGICAL ONCOLOGY
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.5.1.0